Concepedia

Author

Michele Mayo

AstraZeneca (United States)ORCID

Also Known As

M Mayo, M. Mayo, M.F. Mayo, MICHELE F. MAYO, Mayo M., Mayo, M., Michele F Mayo, Michele F. Mayo, Michele Mayo

97

Publications

1.5K

Citations

18

H-Index

61

Concepts

All Affiliations

AstraZeneca (United States)ImmunoGen (United States)AstraZeneca (United Kingdom)Woomera TherapeuticsImperial College London
MM

About

Michele Mayo is an author at AstraZeneca (United States) specializing in medicine, drug discovery, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

9

9

855

2

Engineering

2

2

332

3

Health Sciences

1

1

20

4

Natural Sciences

1

1

23

5

Allergy

1

1

42

Michele Mayo

×

21

Publications

1.4K

Citations

18

H-Index

YearCitations

Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance

Yelena Kovtun, Charlene A. Audette, Michele Mayo,

Cancer Research

2010

254

Tumor Delivery and In Vivo Processing of Disulfide-Linked and Thioether-Linked Antibody−Maytansinoid Conjugates

Hans K. Erickson, Wayne C. Widdison, Michele Mayo,

Bioconjugate Chemistry

2009

238

Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL

Tabea Erdmann, Pavel Klener, James T. Lynch,

Blood

2017

103

A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity

Michael L. Miller, Nathan Fishkin, Wěi Li,

Molecular Cancer Therapeutics

2016

100

Design of Antibody−Maytansinoid Conjugates Allows for Efficient Detoxification via Liver Metabolism

Xiuxia Sun, Wayne C. Widdison, Michele Mayo,

Bioconjugate Chemistry

2011

94

A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies

Jutta Deckert, Peter U. Park, Sharon Chicklas,

Blood

2013

92

Leptin concentrations experience a delayed reduction after resistance exercise in men

Bradley C. Nindl, William J. Kraemer, Paul J. Arciero,

Medicine & Science in Sports & Exercise

2002

81

Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models

Kathleen R. Whiteman, Holly A. Johnson, Michele Mayo,

mAbs

2014

64

Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88<sup>L265P</sup> Diffuse Large B-Cell Lymphoma

James S. Scott, Sébastien L. Degorce, Rana Anjum,

Journal of Medicinal Chemistry

2017

56

Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma

Scott A. Ezell, Michele Mayo, Teeru Bihani,

Oncotarget

2014

53

Page 1